Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.68 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832224 | 0.85 | APLNR (0.59) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL1547907 | 0.84 | IDO1 (0.61) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL5154843 | 0.82 | ADRA1A (0.70) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL6183234 | 0.81 | TAAR1 (0.44) | ADRA1ATAAR1AOC3IDO1 | |
| SCHEMBL25308876 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL8867858 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL7524528 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL479514 | 0.81 | TAAR1 (1.00) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL1145887 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL7060410 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227859-B1 | NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS | ALCON INC (CH) | 2006-08-09 | — | — | EP | claimed |
| EP-1666037-A2 | Compositions for stimulating neurite growth | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| US-6943187-B2 | Pyrrolidine derivative hair growth compositions and uses | GPI NIL HOLDINGS, INC. (US) | 2005-09-13 | — | — | US | claimed |
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | AMGEN INC. | 2004-09-23 | — | — | US | claimed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040049046-A1 | Small molecule inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 2004-03-11 | — | — | US | claimed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | claimed |
| US-20020198250-A1 | Pyrrolidine derivative hair growth compositions and uses | GLIAMED, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | claimed |
| JP-2002510302-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-0992492-A1 | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-12 | — | — | EP | claimed |
| WO-2000009124-A1 | PYRROLIDINE DERIVATIVES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-1999062483-A1 | PIPECOLIC ACID DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | claimed |
| US-5859031-A | Small molecule inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998055091-A1 | PYRROLIDINE DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-10 | — | — | WO | claimed |
| EP-0769006-A4 | — | GUILFORD PHARM INC (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0769006-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1997-04-23 | — | — | EP | claimed |
| WO-1996040633-A9 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | — | 1997-02-27 | — | — | WO | claimed |
| WO-1996040633-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | GAP43, CHAT, MYOC | ADRA1A 2840/4885TAAR1 895/4885AOC3 540/4885 |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | ADRA1A 311/4885TAAR1 1662/4885AOC3 792/4885 |
| US-20040049046-A1 | Small molecule inhibitors of rotamase enzyme activity | FKBP8, FKBP14, PREP | ADRA1A 4429/4885TAAR1 4415/4885AOC3 3781/4885 |
| US-20020198250-A1 | Pyrrolidine derivative hair growth compositions and uses | MKI67, PLOD2, HDGF | ADRA1A 4220/4885TAAR1 2701/4885AOC3 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.